May 2019—Roche and Spark Therapeutics entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics for about $4.3 billion.
Spark Therapeutics, based in Philadelphia, is a pharmaceutical company that develops gene therapies for genetic diseases, including blindness, hemophilia, lysosomal storage disorders, and neurodegenerative diseases. The company will continue its operations in Philadelphia as an independent company within the Roche Group.
Spark Therapeutics’ lead clinical asset is SPK-8011, a novel gene therapy for the treatment of hemophilia A, which is expected to start phase three trials this year.
Roche, +41 61 681 9320
Spark Therapeutics, 215-220-9300